Business
Investor Webinar
TheraCryf plc will host an investor webinar on April 24, 2026, at 10:00 am BST, featuring the CEO and COO to discuss progress in their lead orexin-1 receptor antagonist program for addiction, which is moving towards clinical readiness and first-in-human studies. The company is also advancing its dopamine transporter modulator program for fatigue and has a legacy oncology program. Investors can submit questions in advance via the Investor Meet Company platform. Disclaimer*
About this update from Theracryf Plc
21 April 2026 TheraCryf plc ("TheraCryf", the "Company" or the "Group") Investor Webinar TheraCryf plc (AIM: TCF), the biotech company developing new medicines for addiction and other neuropsychiatric disorders, today announces that Dr Huw Jones, Chief Executive Officer and Dr Helen Kuhlman, Chief Operating Officer, will host an investor webinar on Friday, 24 April 2026 at 10.00 am (BST). The webinar will focus on the Company's recent announcements, including progress in its lead orexin-1 (Ox-1) receptor antagonist programme for addiction as it moves towards clinical readiness, alongside broader strategic developments as TheraCryf advances Ox-1 towards first-in-human studies. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until Thursday, 23 April 2026, 9.00 am (BST), or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet TheraCryf via: https://www.investormeetcompany.com/theracryf-plc/register-investor Investors who already follow TheraCryf on the Investor Meet Company platform will automatically be invited. -Ends- Enquiries TheraCryf plc Dr Huw Jones, CEO Toni Hänninen, CFO Dr Helen Kuhlman, COO +44 (0)1625 315 090 [email protected] Singer Capital Markets (NOMAD & Joint Broker) Phil Davies / Patrick Weaver +44 (0)20 7496 3000 Turner Pope Investments (Joint Broker) Guy McDougall / Andy Thacker +44 (0)20 3657 0050 Northstar Communications (Investor Relations) Sarah Hollins +44 (0)113 730 3896 [email protected] About TheraCryf TheraCryf plc is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of significant unmet medical need within central nervous system (CNS) disorders. The Group's lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders. The programme has already been heavily de-risked for both safety/tolerability and efficacy in previous testing and is fully funded through final pre-clinical trials to clinical readiness, with regulatory su...